Introduction: Fixed-combination intraocular pressure (IOP)-lowering medications simplify treatment regimens for patients requiring 2 ocular hypotensive agents to maintain sufficiently low IOP. The aim of this study was to evaluate the safety and efficacy of fixedcombination brinzolamide 1%/brimonidine 0.2% (BBFC) versus concomitant administration of brinzolamide 1% plus brimonidine 0.2% (BRINZ ? BRIM) in patients with open-angle glaucoma or ocular hypertension. Methods: This was a prospective, phase 3, multicenter, double-masked, 6-month trial. Patients who had insufficient IOP control with monotherapy or who were receiving 2 IOPlowering medications were randomized 1:1 to receive twice-daily BBFC or BRINZ ? BRIM. IOP was assessed at 9 a.m. and 11 a.m. during week 2, week 6, month 3, and month 6 visits. The primary efficacy endpoint was mean diurnal IOP change from baseline to month 3; noninferiority was concluded if the upper limit of the 95% CI of the between-group difference was\1.5 mmHg. Supportive endpoints included mean IOP, IOP change from baseline, and percentage of patients with IOP\18 mmHg. Adverse events were recorded. Results: The mean diurnal IOP change from baseline with BBFC (least squares mean ± standard error -8.5 ± 0.16 mmHg) was noninferior to that with BRINZ ? BRIM (-8.3 ± 0.16 mmHg; mean difference -0.1 mmHg; 95% CI -0.5 to 0.2 mmHg). The upper limits of the Trial registration: ClinicalTrials.gov #NCT01309204. Electronic supplementary material The online version of this article (95% CIs were\1.5 mmHg at all time points. Decreases from baseline[8 mmHg were observed for least squares mean diurnal IOP in both groups as early as week 2 and continued to the end of the study. The results of all other supportive endpoints were similar to the primary efficacy endpoint. The most common ocular adverse drug reactions were hyperemia of the eye (reported as ocular or conjunctival hyperemia), visual disturbances, ocular allergic reactions, and ocular discomfort.
INTRODUCTION
Glaucoma is associated with significant disability and global burden. It is without question the most common cause of irreversible blindness globally and is second only to cataracts as the most common cause of blindness overall [1] . Increased intraocular pressure (IOP) is a risk factor for worsening glaucoma-related neuropathy [2] [3] [4] [5] ; therefore, the primary treatment goal is to achieve an IOP within an acceptable target range [4] . First-line therapies for IOP reduction in developed countries include prostaglandin analogs and b-blockers; other treatment options include a 2 -adrenergic agonists (e.g., brimonidine), carbonic anhydrase inhibitors (e.g., brinzolamide), and parasympathomimetics [4] .
Monotherapy is often insufficient to achieve target IOP; thus, combination therapy may be required [4, 6] . In addition to robust IOPlowering efficacy, fixed-combination therapies provide multiple benefits versus treatment with the corresponding separate medications [7] . These include potentially lower cost, simplified treatment regimens, improved treatment compliance, reduced risk of drug washout, and decreased risk of corneal and ocular surface damage associated with cumulative exposure to preservatives [8] [9] [10] [11] [12] .
For example, the preservative benzalkonium chloride is used in many topical glaucoma medications, but some studies suggest that it may be associated with corneal and conjunctival cell damage and inflammation [13, 14] , tear film disruption [15] , and symptoms of ocular surface disease [16] following chronic exposure. Fixedcombination glaucoma medications reduce overall preservative burden; however, all currently available fixed-combination formulations contain a b-blocker and, therefore, may be contraindicated in patients with certain medical conditions [17, 18] .
A fixed combination of the carbonic anhydrase inhibitor brinzolamide 1% and the a 2 -adrenergic agonist brimonidine 0.2% (BBFC; Simbrinza Ò , Alcon Laboratories, Inc., Fort Worth, TX, USA) was approved in the United States in April 2013. BBFC, which is indicated for the reduction of elevated IOP in patients with primary open-angle glaucoma or ocular hypertension, exerts its IOP-lowering efficacy via two complementary mechanisms: decreased aqueous production by brimonidine and brinzolamide and increased aqueous outflow with brimonidine [4] . In clinical trials, BBFC administered three times daily (TID; a dosing regimen consistent with the approved dosing regimens of brinzolamide and brimonidine in the United States) was more effective in lowering IOP than brinzolamide or brimonidine as monotherapy, and BBFC had a safety profile similar to that of the individual components [12, [19] [20] [21] 
METHODS

Study Design and Intervention
This was a phase 3, randomized, multicenter, Portability and Accountability Act (HIPAA) and the ethical standards set forth by the
Declaration of Helsinki and Good Clinical
Practice. All patients provided written informed consent before study initiation.
During the screening visit, patients reported their medical histories and concomitant medications, were evaluated against inclusion and exclusion criteria, and received a medical examination (e.g., IOP measurements). After an appropriate washout period (as previously reported [19, 20] ), patients confirmed discontinuation of ocular hypotensive agents and underwent bilateral IOP measurement at 9 a.m. and 11 a.m. at 2 eligibility visits. Patients were eligible for inclusion if mean IOP measurements for C1 eye (the same eye) were 24-36 mmHg at 9 a.m. and 21-36 mmHg at 11 a.m. during both eligibility visits; mean IOP could not exceed 36 mmHg in either eye at any time during the study. Time-matched IOP measurements from each eligibility visit were averaged to calculate the baseline IOP at each time point.
Eligible patients were randomly assigned 1:1 using an interactive web response system to receive BBFC or BRINZ ? BRIM for 6 months.
Randomization was determined using a block design, stratified by study center and mean 9 a.m. baseline IOP (24) (25) (26) (27) 
Patients
Complete patient inclusion and exclusion criteria are provided in Table 1 .
Outcomes
The primary efficacy endpoint was the mean change from baseline to month 3 in diurnal IOP, which was calculated as the average of the 9 a.m. and 11 a.m. time points. The 9 a.m. and 11 a.m. time points were selected because they correspond approximately to trough (12 h postinstillation) and peak (?2 h postinstillation) IOP-lowering efficacy of brinzolamide and brimonidine [23] . At trough (9 a.m.) and peak (?2 h; 11 a.m.), IOP was expected to be at the highest and lowest points, respectively, on the diurnal curve for most patients.
Supportive efficacy endpoints included:
• Mean diurnal IOP change from baseline to week 2, week 6, and month 6;
• Mean IOP at each study visit and time point (i.e., week 2, week 6, month 3, and month 6 at 9 a.m. and 11 a.m.);
• Mean IOP change from baseline at each study visit and time point;
• Mean IOP percentage change from baseline at each study visit and time point;
• Percentage of patients with IOP\18 mmHg at each study visit and time point.
Intraocular pressure was measured by a tonometer operator and a tonometer reader; patient treatment was masked to the operator and reader throughout the study. At each time point (i.e., 9 a.m. and 11 a.m.) of each treatment study visit, at least two consecutive measures of IOP were obtained for each eye using a Goldmann applanation tonometer. If the initial two measurements differed by[4 mmHg, a third measurement was taken and the two most similar measurements averaged; if all measurements differed by similar amounts, all three were averaged. One eye from each patient was designated the ''study eye,'' and data from only this eye were included in the efficacy analyses. Among patients who dosed only one eye during the study, the dosed eye was selected as the study eye. If both eyes were dosed during the study, the worse evaluable eye (defined as the eye with the higher IOP at 9 a.m. averaged across the two eligibility visits) was selected as the study eye. If IOP was equal in both eyes, the eye with the higher IOP at 11 a.m. (averaged across two eligibility visits) was designated as the study eye; if IOP measurements were equal in both eyes at 11 a.m., the right eye was selected.
Safety outcomes included adverse event (AE) reporting, best-corrected visual acuity (BCVA) corneal thickness, visual field function, slitlamp biomicroscopy (cornea, iris/anterior chamber, lens, eyelids), dilated fundus examination (vitreous, retina/macula/choroid, optic nerve including cup-to-disc ratio), and cardiovascular assessment (pulse, blood pressure). AE data were collected at all For the noninferiority test, two-sided 95% CIs were constructed for the between-group differences in mean change from baseline in diurnal IOP at each visit and time point on an observed-case basis in the PP population.
Noninferiority of BBFC to BRINZ ? BRIM was established if the upper limit of the 95% CI of the between-group difference in mean change from baseline to month 3 in diurnal IOP was\1.5 mmHg. A Cochran-Mantel-Haenszel test was used to analyze between-group differences for categorical parameters across study center and baseline IOP strata. Safety data were examined in all patients who were exposed to study drug and were summarized using descriptive statistics. All analyses were performed using SAS Ò software (SAS Institute, Cary, NC, USA).
A total of approximately 820 patients were planned to be enrolled. With 340 patients per group in the primary efficacy analysis, the study would have at least 90% power that a two-sided 95% CI of the difference in mean IOP between the treatment groups at month 3 would be within ±1.5 mmHg. Because only one side of this tolerance region was relevant for the noninferiority comparison, the upper limit of 
RESULTS
Patients
In total, 1,190 patients were enrolled and 890
were randomly allocated to treatment with BBFC (n = 451) or BRINZ ? BRIM (n = 439; Fig. 1 Table 3) . The percentage of patients achieving IOP\18 mmHg was also similar with both treatments; at the time of peak morning Week 6 IOP data (not shown) were similar to efficacy data at other study visits.
Safety
The safety profile of BBFC was consistent with the known safety profiles of its individual components, and BBFC did not result in additional risk to patients.
A similar percentage of patients receiving BBFC or BRINZ ? BRIM experienced serious AEs (SAEs; i.e., approximately 2% in both treatment groups; Table 4 ). One patient who received BRINZ ? BRIM died of a myocardial infarction that was assessed as unrelated to study drug.
The majority of SAEs were reported as single events, resolved over the course of the study, and did not interrupt use of the study drug. No patterns emerged to suggest a patient-safety issue with BBFC, and of all SAEs, only corneal erosion was considered related to study drug.
All other reported SAEs were assessed by the study investigator as unrelated to the use of study medication.
Adverse drug reactions (ADRs; i.e., AEs assessed as related to treatment) were reported in a similar percentage of patients receiving BBFC (23.5%) and BRINZ ? BRIM (26.8%; Table 4 ). The majority of ADRs reported during the study were local ocular side effects with a known causal association with the individual components. The most common ocular ADRs were hyperemia of the eye (reported as ocular or conjunctival hyperemia), visual disturbances, ocular allergic type reactions, and ocular discomfort. Common systemic ADRs reported in the study included dysgeusia, oral dryness, and fatigue/drowsiness. Study treatment was discontinued because of an AE in 13.3% of patients in the BRINZ ? BRIM group and 10.6% of patients in the BBFC group; discontinuations because of a treatment-related nonserious AE were reported for 11.7% and 10.0% of patients receiving BRINZ ? BRIM and BBFC, respectively ( Table 4 ). The majority of discontinuations in both groups were attributable to local ocular events associated with the use of the individual components (e.g., ocular discomfort, hyperemia of the eye, ocular allergies). No clinically meaningful alterations in other ocular or cardiovascular assessments were observed.
DISCUSSION
In this randomized phase 3 trial, change in LS mean ± SE diurnal IOP from baseline was similar with BBFC (-8.5 ± 0.16 mmHg) and BRINZ ? BRIM (-8.3 ± 0.16 mmHg; LS mean between-group difference -0.1 mmHg; 95% CI -0.5 to 0.2 mmHg) after 3 months, and the criterion for noninferiority was met. The safety profile of BBFC was consistent with the known safety profiles of the individual components administered concomitantly; no new AEs were observed.
Intraocular pressure reduction was previously demonstrated to be significantly greater with BBFC administered BID compared with either BRINZ or BRIM monotherapy administered BID [22] . In the current study, the IOP-lowering efficacy of BID BBFC was similar to that of BID BRINZ ? BRIM.
Furthermore, IOP reduction achieved with BBFC administered BID (mean percentage IOP reductions from baseline at 3 months, 28.6-37.6%) was similar to that previously observed with BBFC administered TID over similar morning time points at 3 months (approximately 24-34%) [19] . Longer term IOP reductions at 6 months were also similar with BID versus TID dosing of BBFC [12] . The safety of BBFC was consistent with BRINZ ? BRIM and the known safety profiles of the individual components and did not result in additional risk to patients. The incidence of SAEs with BBFC administered BID (2.4%) was similar to that previously reported for this dosing regimen in a similar patient population (2.6%) [22] . The safety profile for BBFC was consistent between the 2 studies; the most common BBFC-related ADR in both trials was hyperemia [22] . The rate of ADRs in the current study after 6 months of BID treatment with BBFC (23.5%) was similar to that of BRINZ ? BRIM (26.8%) and was lower than the rate reported with BBFC administered TID at 6 months (33.0%) [12] . [9] , increased tolerability and reduction of ocular symptoms through reduced cumulative exposure to preservatives [24] , reduced cost [25, 26] , and elimination of potential washout effects associated with instillation of multiple concomitant drops [8] . In addition, cumulative exposure to the components of glaucoma medications may lead to corneal and conjunctival alterations and ocular surface damage [10, 11] . Preservatives (e.g., benzalkonium chloride) in glaucoma medications are associated with ocular surface toxicity and damage that decrease patients' quality of life [11, 27, 28] . Active compounds in glaucoma medications may contribute to inflammation, and epithelial modifications have been observed by laser scanning confocal microscopy in patients receiving more than two medications [11] [30, 31] . As the only fixed combination glaucoma therapy currently available that does not contain a b-blocker, BBFC may be particularly useful for those patients for whom a b-blocker such as timolol is contraindicated.
A limitation of this clinical study was that it aimed to demonstrate noninferior efficacy and safety of a fixed combination versus concomitant administration of the same individual medications, which prevented direct comparison with other classes of IOPlowering medications (e.g., latanoprost/timolol combinations); therefore, subsequent trials will be required to address this comparison. Also, IOP was not assessed throughout a full diurnal period and included only two time points, which prevented comparison with previous TID dosing studies at other daily time periods. Future studies evaluating the noninferiority of BBFC compared with its unfixed components in additional patient populations (e.g., patients with normal tension glaucoma) will provide additional valuable information about the efficacy of BBFC. 
CONCLUSIONS
